Global Keratoconjunctivitis Market, By Drug Class (NSAIDS, Corticosteroids, Antibiotics, Antivirals, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Keratoconjunctivitis Market Analysis and Size
The global keratoconjunctivitis market is expected to witness significant growth during the forecast period. Keratoconjunctivitis is an often under diagnosed and undertreated health problem due to few patients having keratoconjunctivitis with allergic symptoms seek medical attention. Risk factors include age, gender, and family and personal history. About 95% people with this condition having history of atopic dermatitis, with 87% suffering from asthma earlier in life. Young people are at the highest risk of developing this condition. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global keratoconjunctivitis market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Keratoconjunctivitis is a severe type of eye infection that is characterised by the inflammation of the both cornea and conjunctiva of the eyes. It is usually caused by different allergies, viruses, or bacteria and some are also associated with autoimmune disorders or minor injury. In keratoconjunctivitis, patient mostly experience redness of the eye, blurred vision and eye pain.
Keratoconjunctivitis Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (NSAIDS, Corticosteroids, Antibiotics, Antivirals, Others), Route of Administration (Oral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Bausch Health Companies Inc. (U.S.), Merck & Co. Inc. (U.S.), Pfizer Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Amorphex Therapeutics Holdings, Inc (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Lupin (India), Cipla Inc (India)
|
|
Market Opportunities
|
|
Global Keratoconjunctivitis Market Dynamics
Drivers
- Increase in Keratoconjunctivitis Cases
Keratoconjunctivitis is a rare conjunctivitis condition that occurs around 1 in 10,000 persons. The chances of keratoconjunctivitis infections varies with country and season. It most commonly occurs in warmer climates. This infection is more common in men compared to women. It is somewhat related to atopic dermatitis, which affects about 3% of the population worldwide wherein about 15 to 67% of people have certain types of eye infections. This boost the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to increase the market growth. The segment is projected to accelerate the global market as many products are available in capsule form and tablet form and it is a very feasible route of administration.
Opportunities
- Rapid Urbanization and Pollution Levels
Rapid urbanization and augmented particulate pollution have increased the occurrence of keratoconjunctivitis in several countries, such as India and China. However, factors such as a dearth of awareness among the general population regarding eye disorders and lack of health insurance control the market in France, Germany, Italy, and Spain.
- Increasing Demand for Retail Pharmacies
Opportunities for market growth are created by the rise in the number of keratoconjunctivitis treatments provided by retail pharmacies and the rise in the number of retail pharmacies in developed nations. Patients also favour retail pharmacies because they are convenient for acquiring medications.
Restraints/Challenges
- Lack of skilled professionals
The lack of qualified personnel who are unable to treat the patients with appropriate eye lubricants could curb the growth of the global keratoconjunctivitis market over a forecast period.
- Risk of Side-Effects
The associated side effects that comes with the application of drugs of keratoconjunctivitis hampers the market growth. Serious side-effects such as eye pain, change in vision, continued eye redness/irritation and severe side effects such as allergy hampers the market's growth.
This global keratoconjunctivitis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global keratoconjunctivitis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Keratoconjunctivitis Market
The COVID-19 pandemic greatly impacted the pharmaceutical industry's entire supply chain, mostly due to strict lockdown in several regions. Also, the demand for conjunctivitis drugs is increasing in this COVID-19 pandemic, due to increasing number of conjunctivitis cases, in which conjunctivitis was the only symptom in COVID-19 positive patients. Thus, this will leave a significant impact on the global keratoconjunctivitis market.
Global Keratoconjunctivitis Market Scope
The global keratoconjunctivitis market is segmented on the basis of drug class, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drug Class
- NSAIDS
- Corticosteroids
- Antibiotics
- Antivirals
- Others
Route of Administration
- Oral
- Topical
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Keratoconjunctivitis Market Regional Analysis/Insights
The global keratoconjunctivitis market is analysed and market size insights and trends are provided by drug class, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global keratoconjunctivitis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global keratoconjunctivitis market throughout the forecasted period due to the increase government initiatives and developing healthcare facilities.
North America dominates the market due to more cases of keratoconjunctivitis, increased awareness about the keratoconjunctivitis treatment options, and advanced healthcare facilities.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Keratoconjunctivitis Market Share Analysis
The global keratoconjunctivitis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related global keratoconjunctivitis market
Key players operating in the global keratoconjunctivitis market include:
- Bausch Health Companies Inc. (U.S.)
- Merck & Co. Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Amorphex Therapeutics Holdings, Inc (U.S.)
- Bayer AG (Germany)
- Novartis AG (Switzerland)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Lupin (India)
- Cipla Inc (India)
SKU-